BeOne Medicines (ONC) Depreciation & Amortization (CF) (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Depreciation & Amortization (CF) data on file, last reported at $41.1 million in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 25.42% year-over-year to $41.1 million in Q1 2026; TTM through Mar 2026 was $150.0 million, a 16.31% decrease from a year earlier, with the FY2025 full-year figure at $141.7 million, down 17.51% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $41.1 million, up from $36.0 million in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for ONC reached as high as $71.3 million in Q3 2024 and fell as low as $15.5 million in Q2 2022.
• Historically, Depreciation & Amortization (CF) has averaged $29.9 million across 5 years, with a median of $24.9 million in 2024.
• Across the five-year window, Depreciation & Amortization (CF) jumped 231.44% in 2024 and tumbled 47.7% in 2025, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $18.0 million in 2022, then surged by 32.21% to $23.8 million in 2023, then surged by 110.95% to $50.2 million in 2024, then decreased by 28.38% to $36.0 million in 2025, then advanced by 14.34% to $41.1 million in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $41.1 million in Q1 2026, $36.0 million in Q4 2025, and $37.3 million in Q3 2025.